Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs

American Journal of Physiology - Endocrinology and Metabolism

Volumn 296, Issue 6, 2009, Pages

  Richey, Joyce M ^a   Woolcott, Orison O ^a   Stefanovski, Darko ^a   Harrison, L Nicole ^a   Zheng, Dan ^a   Lottati, Maya ^a   Hsu, Isabel R ^a   Kim, Stella P ^a   Kabir, Morvarid ^a   Catalano, Karyn J ^a   Chiu, Jenny D ^a   Ionut, Viorica ^a   Kolka, Cathryn ^a   Mooradian, Vahe ^a   Bergman, Richard N ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adipose tissue; Body weight; Energy expenditure; Magnetic resonance; Resting metabolic rate

Indexed keywords

PLACEBO; RIMONABANT;

ABDOMINAL FAT; ANIMAL EXPERIMENT; ARTICLE; BASAL METABOLIC RATE; CALORIMETRY; CONTROLLED STUDY; ENERGY EXPENDITURE; EXPERIMENTAL DOG; FOOD INTAKE; INTRAABDOMINAL FAT; LIPID DIET; LIPID STORAGE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SUBCUTANEOUS FAT; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; DIETARY FATS; DOGS; EATING; ENERGY METABOLISM; INTRA-ABDOMINAL FAT; MAGNETIC RESONANCE IMAGING; MALE; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SUBCUTANEOUS FAT, ABDOMINAL;

EID: 66849131405     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90972.2008     Document Type: Article

References (48)

1. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63: 908-914, 2003. (Pubitemid 36368998)
2. Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M, Hucking K, Ader M. Why visceral fat is bad: Mechanisms of the metabolic syndrome. Obesity 14: 16S-S19, 2006.
3. Bergman RN, Kim SP, Hsu IR, Catalano KJ, Chiu JD, Kabir M, Richey JM, Ader M. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 120: S3-S8, 2007. (Pubitemid 46216205)
4. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45: 633-638, 1996. (Pubitemid 26140548)
5. Collin P, Chapados N, Dufresne E, Corriveau P, Imbeault P, Lavoie JM. Time course of changes in in vitro lipolysis of intra-abdominal fat depots in relation to high-fat diet-induced hepatic steatosis in rats. Br J Nutr 96: 268-275, 2006. (Pubitemid 46470094)
6. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423-431, 2003. (Pubitemid 38063771)
7. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121-2134, 2005. (Pubitemid 41653104)
8. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7: 438-455, 2008.
9. Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y, Richard D. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary- adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 55: 3403-3410, 2006. (Pubitemid 44923599)
10. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838-2843, 2005. (Pubitemid 41401077)
11. Ferrer-Lorente R, Cabot C, Fernandez-Lopez JA, Alemany M. Effects of combined oleoyl-estrone and rimonabant on overweight rats. J Pharmacol Sci 104: 176-182, 2007. (Pubitemid 46974992)
12. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69: 471-478, 2006. (Pubitemid 43121944)
13. Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med 120: S10-S16, 2007. (Pubitemid 47284982)
14. Hayashi T, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. Diabetes 57: 1269-1275, 2008.
15. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 149: 2557-2566, 2008.
16. Herling AW, Kilp S, Juretschke HP, Neumann-Haefelin C, Gerl M, Kramer W. Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant. Int J Obes (Lond) 32: 1363-1372, 2008.
17. Hsu IR, Kabir M, Stefanovski D, Woolcott O, Zheng D, Catalano KJ, Chiu JD, Kim SP, Harrison LN, Lottati M, Ionut V, Bergman RN, Richey JM. Accumulation of large adipocytes in omental and subcutaneous fat depots during development of obesity in dogs prevented by rimonabant (Abstract). Diabetologia 50, Suppl 1: P0664, 2007.
18. Jarbe TU, Andrzejewski ME, DiPatrizio NV. Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 73: 911-919, 2002. (Pubitemid 35246241)
19. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846, 2006. (Pubitemid 46024990)
20. Kamel EG, McNeill G, Van Wijk MC. Change in intra-abdominal adipose tissue volume during weight loss in obese men and women: correlation between magnetic resonance imaging and anthropometric measurements. Int J Obes Relat Metab Disord 24: 607-613, 2000. (Pubitemid 30323493)
21. Kim DM, Yoon SJ, Ahn CW, Cha BS, Lim SK, Kim KR, Lee HC, Huh KB. Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diabetes Res Clin Pract 66, Suppl 1: S139-S144, 2004. (Pubitemid 39572601)
22. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117: 2621-2637, 2007. (Pubitemid 47494363)
23. Kim SP, Catalano KJ, Hsu IR, Chiu JD, Richey JM, Bergman RN. Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia. Am J Physiol Endocrinol Metab 292: E1590-E1598, 2007. (Pubitemid 47084693)
24. Kim SP, Ellmerer M, Kirkman EL, Bergman RN. β-Cell "rest" accompanies reduced first-pass hepatic insulin extraction in the insulin resistant, fat-fed canine model. Am J Physiol Endocrinol Metab 292: E1581-E1589, 2007. (Pubitemid 47084692)
25. Kim SP, Ellmerer M, Van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes 52: 2453-2460, 2003. (Pubitemid 37210532)
26. Kissebah AH. Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease? Diabetes Res Clin Pract Suppl 30: 25-30, 1996. (Pubitemid 126352573)
27. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, Mohammed BS. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 350: 2549-2557, 2004. (Pubitemid 38758542)
28. Kunz I, Meier MK, Bourson A, Fisseha M, Schilling W. Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. Int J Obes (Lond) 32: 863-870, 2008.
29. Lowell BB, Spiegelman BM. Towards a molecular understanding of adaptive thermogenesis. Nature 404: 652-660, 2000. (Pubitemid 30205070)
30. Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, DeFronzo RA. Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 283: E1135-E1143, 2002. (Pubitemid 35340618)
31. Mohammed BS, Cohen S, Reeds D, Young VL, Klein S. Long-term effects of large-volume liposuction on metabolic risk factors for coronary heart disease. Obesity (Silver Spring) 16: 2648-2651, 2008.
32. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Rizzuto R, Bernante P, Federspil G, Vettor R. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 92: 4810-4819, 2007. (Pubitemid 350223464)
33. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73-100, 2006. (Pubitemid 43228239)
34. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, and for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761-775, 2006. (Pubitemid 43244304)
35. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, Janiak P, Herbert JM. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7: 65-72, 2005.
36. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R345-R353, 2003. (Pubitemid 36120150)
37. Ravussin E, Burnand B, Schutz Y, Jequier E. Twenty-four-hour energy expenditure and resting metabolic rate in obese, moderately obese, and control subjects. Am J Clin Nutr 35: 566-573, 1982.
38. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF, Haffaf Y, Cesari M, Festy F. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 126: 177-187, 2006.
39. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368: 1660-1672, 2006. (Pubitemid 46048528)
40. Tiikkainen M, Bergholm R, Rissanen A, Aro A, Salminen I, Tamminen M, Teramo K, Yki-Jarvinen H. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr 79: 22-30, 2004. (Pubitemid 41132058)
41. Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab 7: 410-420, 2008.
42. Tulloch-Reid MK, Hanson RL, Sebring NG, Reynolds JC, Premkumar A, Genovese DJ, Sumner AE. Both subcutaneous and visceral adipose tissue correlate highly with insulin resistance in African Americans. Obesity Res 12: 1352-1359, 2004.
43. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389-1397, 2005. (Pubitemid 40523733)
44. Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Haffner SM, Saad MF, Bergman RN. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 52: 2490-2496, 2003. (Pubitemid 37210536)
45. Weir JBdV. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 109: 1-9, 1949.
46. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053, 2004.
47. Wueest S, Rapold RA, Rytka JM, Schoenle EJ, Konrad D. Basal lipolysis, not the degree of insulin resistance, differentiates large from small isolated adipocytes in high-fat fed mice. Diabetologia 52: 541-546, 2009.
48. Yip I, Go VL, Hershman JM, Wang HJ, Elashoff R, DeShields S, Liu Y, Heber D. Insulin-leptin-visceral fat relation during weight loss. Pancreas 23: 197-203, 2001. (Pubitemid 32692129)